



## OPEN ACCESS

EDITED AND REVIEWED BY  
Peter Brossart,  
University of Bonn, Germany

## \*CORRESPONDENCE

Cheng Qian  
✉ cqian8634@gmail.com  
Zhi Yang  
✉ yz2003can@126.com

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 19 December 2024  
ACCEPTED 10 January 2025  
PUBLISHED 31 January 2025

## CITATION

Zhang C, Wang L, Zhang Q, Shen J, Huang X, Wang M, Huang Y, Chen J, Xu Y, Zhao W, Qi Y, Li Y, Ou Y, Yang Z and Qian C (2025) Corrigendum: Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma. *Front. Immunol.* 16:1548247. doi: 10.3389/fimmu.2025.1548247

## COPYRIGHT

© 2025 Zhang, Wang, Zhang, Shen, Huang, Wang, Huang, Chen, Xu, Zhao, Qi, Li, Ou, Yang and Qian. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma

Chengcheng Zhang<sup>1†</sup>, Linling Wang<sup>2†</sup>, Qianzhen Zhang<sup>2</sup>, Junjie Shen<sup>2</sup>, Xia Huang<sup>2</sup>, Meiling Wang<sup>2</sup>, Yi Huang<sup>2</sup>, Jun Chen<sup>2</sup>, Yanmin Xu<sup>2</sup>, Wenxu Zhao<sup>2</sup>, Yanan Qi<sup>2</sup>, Yunyan Li<sup>2</sup>, Yanjiao Ou<sup>1</sup>, Zhi Yang<sup>2\*</sup> and Cheng Qian<sup>2\*</sup>

<sup>1</sup>Department of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing, China, <sup>2</sup>Chongqing Key Laboratory of Gene and Cell Therapy, Institute of Precision Medicine and Biotechnology, Chongqing Precision Biotech Co. Ltd., Chongqing, China

## KEYWORDS

chimeric antigen receptor T cells, carcinoembryonic antigen, single-chain fragment variable, affinity, cell therapy

## A Corrigendum on

### Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma


By Zhang C, Wang L, Zhang Q, Shen J, Huang X, Wang M, Huang Y, Chen J, Xu Y, Zhao W, Qi Y, Li Y, Ou Y, Yang Z and Qian C (2023) *Front. Immunol.* 14:1182409. doi: 10.3389/fimmu.2023.1182409

In the published article, there was an error in **Figure 7A** as published. Among a large amount of pictures for selection, we found two graphs identical since they were not classified correctly. The corrected **Figure 7A** and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



**FIGURE 7** M5A CAR-T cells exhibited superior tumor suppression in the xenograft model in NOG mice. **(A)** Each mouse was implanted with  $1 \times 10^6$  LoVo cells (Luc<sup>+</sup>) on day 1 and injected i.v. with  $1 \times 10^7$  CAR-T cells on day 7. Mice were imaged weekly. **(B)** Tumor growth was assessed by calculating the tumor volume. The values are presented as the means  $\pm$  SEMs. The growth of tumors treated with M5A CAR-T cells was potently controlled compared with that of tumors in the other groups. **(C)** The total bioluminescence values were also recorded and compared. The values are presented as the means  $\pm$  SEMs. Statistical analysis was performed by one-way ANOVA. \* =  $p < 0.05$ ; \*\* =  $p < 0.01$ ; and ns, not significant.